Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
| العنوان: | Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement |
|---|---|
| المؤلفون: | Kyeong Hye Park, Se Hwa Kim, Jung Min Lee, Kyung Ae Lee, Min Jeong Kwon, Jung Soo Lim, Ha Young Kim, Dong Jun Lim, Kee Ho Song, Eun Jig Lee, Hyun Koo Yoon, Heung Yong Jin, Dong Yeob Shin, Jung Hee Kim, Dong Sun Kim, Jin Hwa Kim, Seong-Su Moon, Seungjoon Oh, Kwang Joon Kim, Chong Hwa Kim, Cheol Ryong Ku, Dae Jung Kim, Sang Ouk Chin, Sung Woon Kim, Byung Joon Kim |
| المصدر: | Endocrinology and Metabolism, Vol 34, Iss 1, Pp 53-62 (2019) Endocrinology and Metabolism |
| بيانات النشر: | Korean Endocrine Society, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Position statement, medicine.medical_specialty, Consensus, Antineoplastic Agents, Hormonal, Endocrinology, Diabetes and Metabolism, Dose interval, Decision Making, Antineoplastic Agents, Somatostatin analogues, Octreotide, Lanreotide, Injections, Intramuscular, Peptides, Cyclic, lcsh:Diseases of the endocrine glands. Clinical endocrinology, Special Article, chemistry.chemical_compound, Endocrinology, Republic of Korea, Acromegaly, Health insurance, Humans, Medicine, Expert Testimony, Insurance, Health, lcsh:RC648-665, Medical treatment, business.industry, Neuroendocrinology, medicine.disease, Pasireotide, Somatostatin, Attitude, chemistry, Family medicine, Practice Guidelines as Topic, Preoperative Period, business |
| الوصف: | The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach. |
| تدمد: | 2093-5978 2093-596X |
| DOI: | 10.3803/enm.2019.34.1.53 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a319ff9a9bd40d33975edb6b205269e https://doi.org/10.3803/enm.2019.34.1.53 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6a319ff9a9bd40d33975edb6b205269e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20935978 2093596X |
|---|---|
| DOI: | 10.3803/enm.2019.34.1.53 |